JP2022529929A5 - - Google Patents
Info
- Publication number
- JP2022529929A5 JP2022529929A5 JP2021561599A JP2021561599A JP2022529929A5 JP 2022529929 A5 JP2022529929 A5 JP 2022529929A5 JP 2021561599 A JP2021561599 A JP 2021561599A JP 2021561599 A JP2021561599 A JP 2021561599A JP 2022529929 A5 JP2022529929 A5 JP 2022529929A5
- Authority
- JP
- Japan
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025122188A JP2025169256A (ja) | 2019-04-17 | 2025-07-22 | α４β７阻害薬及びＩＬ－２３阻害薬の併用療法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962835349P | 2019-04-17 | 2019-04-17 | |
| US62/835,349 | 2019-04-17 | ||
| PCT/US2020/028861 WO2020215019A1 (en) | 2019-04-17 | 2020-04-17 | Alpha4beta7 inhibitor and il-23 inhibitor combination therapy |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025122188A Division JP2025169256A (ja) | 2019-04-17 | 2025-07-22 | α４β７阻害薬及びＩＬ－２３阻害薬の併用療法 |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2022529929A JP2022529929A (ja) | 2022-06-27 |
| JP2022529929A5 true JP2022529929A5 (https=) | 2023-04-25 |
| JPWO2020215019A5 JPWO2020215019A5 (https=) | 2023-04-25 |
| JP7778567B2 JP7778567B2 (ja) | 2025-12-02 |
Family
ID=72837950
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021561599A Active JP7778567B2 (ja) | 2019-04-17 | 2020-04-17 | α４β７阻害薬及びＩＬ－２３阻害薬の併用療法 |
| JP2025122188A Pending JP2025169256A (ja) | 2019-04-17 | 2025-07-22 | α４β７阻害薬及びＩＬ－２３阻害薬の併用療法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025122188A Pending JP2025169256A (ja) | 2019-04-17 | 2025-07-22 | α４β７阻害薬及びＩＬ－２３阻害薬の併用療法 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20230096620A1 (https=) |
| EP (1) | EP3956358A4 (https=) |
| JP (2) | JP7778567B2 (https=) |
| MA (1) | MA55735A (https=) |
| WO (1) | WO2020215019A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2023095000A1 (en) * | 2021-11-23 | 2023-06-01 | Janssen Biotech, Inc. | Method of treating ulcerative colitis with anti-il23 specific antibody |
| WO2024249568A1 (en) | 2023-05-30 | 2024-12-05 | Paragon Therapeutics, Inc. | Alpha4beta7 integrin antibody compositions and methods of use |
| CN121889424A (zh) | 2023-08-14 | 2026-04-17 | 派拉冈医疗公司 | α4β7整联蛋白结合蛋白及使用方法 |
| WO2026058045A1 (en) * | 2024-09-12 | 2026-03-19 | Takeda Pharmaceutical Company Limited | Alpha4beta7 inhibitor and il-23 inhibitor combination therapy |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7147851B1 (en) * | 1996-08-15 | 2006-12-12 | Millennium Pharmaceuticals, Inc. | Humanized immunoglobulin reactive with α4β7 integrin |
| US20110212104A1 (en) * | 2008-11-03 | 2011-09-01 | Schering Corporation | Inflammatory bowel disease biomarkers and related methods of treatment |
| DK3311834T3 (da) * | 2011-05-02 | 2026-04-20 | Millennium Pharmaceuticals Inc | Formulering til anti-alfa4beta7-antistof |
| UA116189C2 (uk) * | 2011-05-02 | 2018-02-26 | Мілленніум Фармасьютікалз, Інк. | КОМПОЗИЦІЯ АНТИ-α4β7 АНТИТІЛА |
| MA41636A (fr) * | 2015-03-06 | 2018-01-09 | Millennium Pharm Inc | Méthode de traitement de la cholangite sclérosante primitive |
| DK3277719T3 (da) * | 2015-03-31 | 2022-05-02 | Sorriso Pharmaceuticals Inc | Polypeptider |
| JP6909208B2 (ja) * | 2015-09-17 | 2021-07-28 | アムジェン インコーポレイテッド | Ｉｌ２３経路バイオマーカーを使用するｉｌ２３アンタゴニストに対する臨床応答の予測 |
| WO2017106595A1 (en) * | 2015-12-18 | 2017-06-22 | Sciadonics, Inc. | Lipid formulations containing bioactive fatty acids and a non-fatty acid anti-inflammatory agent |
| JP7162533B2 (ja) * | 2016-05-04 | 2022-10-28 | ミレニアム ファーマシューティカルズ， インコーポレイテッド | 炎症性腸疾患の治療を目的とする三剤併用療法 |
| BR112019012071A2 (pt) * | 2016-12-14 | 2019-11-12 | Progenity Inc | tratamento de uma doença do trato gastrointestinal com um inibidor de integrina |
| JP2020512344A (ja) * | 2017-03-27 | 2020-04-23 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 抗ｉｌ−３６ｒ抗体併用治療 |
| BR112019022268A2 (pt) * | 2017-04-28 | 2020-05-19 | Millennium Pharmaceuticals, Inc. | método para o tratamento de distúrbios pediátricos |
| US20230033021A1 (en) * | 2018-06-20 | 2023-02-02 | Progenity, Inc. | Treatment of a disease of the gastrointestinal tract with an integrin inhibitor |
-
2020
- 2020-04-17 EP EP20792259.2A patent/EP3956358A4/en active Pending
- 2020-04-17 MA MA055735A patent/MA55735A/fr unknown
- 2020-04-17 WO PCT/US2020/028861 patent/WO2020215019A1/en not_active Ceased
- 2020-04-17 JP JP2021561599A patent/JP7778567B2/ja active Active
- 2020-04-17 US US17/604,324 patent/US20230096620A1/en active Pending
-
2025
- 2025-07-22 JP JP2025122188A patent/JP2025169256A/ja active Pending